Background-Atherosclerosis is an inflammatory disease, and extracellular nucleotides are one of the factors possibly involved in vascular inflammation. The P2Y 1 receptor for adenosine 5=-diphosphate has been shown to be involved in the development of atherosclerosis in apolipoprotein E-deficient mice. Our aim is to determine whether the endothelial P2Y 1 receptor plays a role in leukocyte recruitment during vascular inflammation and characterize underlying mechanisms. Methods and Results-We show here that the P2Y 1 receptor plays a role in leukocyte recruitment in inflamed mouse femoral arteries. Moreover, in wild-type bone marrow-transplanted chimeric P2Y 1 -deficient mice with an apolipoprotein E-deficient background, a strong reduction of adhesion molecule-dependent leukocyte recruitment was observed after local injection of tumor necrosis factor ␣ and interleukin 1␤, excluding a role for the platelet or other hematopoietic cell type P2Y 1 in these events. Similarly, the in vitro adhesion of isolated mouse monocytes to tumor necrosis factor ␣-stimulated murine endothelial cell monolayers and their migration across the cell layers were strongly reduced in P2Y 1 -deficient compared with wild-type endothelial cells, as was the expression of the adhesion molecules P-selectin, Vascular cell adhesion molecule 1, and intercellular adhesion molecule 1. Pharmacological inhibition using the selective antagonist MRS2500 also resulted in decreased expression of adhesion molecules. These events are related to the p38 mitogen-activated protein kinase and activating transcription factor 2 pathway. Finally, in vivo administration of MRS2500 resulted in strong reduction of leukocyte recruitment in inflamed femoral arteries of apolipoprotein E-deficient mice. Conclusions-The data highlight a key role of the endothelial P2Y 1 receptor in acute vascular inflammation.
otides also modulate the proliferation and apoptosis of vascular cells. 8 Two families of membrane receptors mediate the effects of extracellular nucleotides: P2X receptors, ligand-gated ion channels, of which 7 subtypes have been identified, and P2Y receptors, which are G protein-coupled receptors comprising 8 subtypes. 10 Although these receptors have been proposed to be obligate players in atherosclerosis, 8 only a few studies have so far investigated the selective contributions of P2Y receptor subtypes to vascular inflammation and atherosclerosis. P2Y 2 receptors have been shown to be involved in the mechanism leading to neointimal hyperplasia after angioplasty. 13, 14, 16 It has also been shown that extracellular nucleotides regulate neutrophil migration by controlling Toll-like receptor 2-induced IL-8 release through concomitant activation of P2Y 2 and P2Y 6 . 17 The P2Y 1 receptor is an adenosine diphosphate (ADP) receptor expressed in a wide range of tissues, including vascular endothelial cells, and in circulating blood cells, such as leukocytes and platelets. 9, 18 It plays a key role in normal hemostasis and in arterial thrombosis, as has been demonstrated in many studies using P2Y 1 -deficient (P2Y 1 Ϫ/Ϫ ) mice and P2Y 1 receptor antagonists. 19 -23 A role of the P2Y 1 receptor in the development of atherosclerosis was recently demonstrated, 24 adding to its relevance as an attractive target for new pharmacological strategies in atherothrombosis. Interestingly, bone marrow transplantation experiments showed that the platelet receptor is not involved in this process, suggesting a possible role of the P2Y 1 receptor expressed in endothelial cells. 24 The aim of our present study was to determine whether the endothelial P2Y 1 receptor plays a part in the recruitment of leukocytes in vivo and/or in vitro, and, if so, to characterize the underlying mechanisms. We found that endothelial P2Y 1 strongly contributes to TNF␣-induced leukocyte recruitment in experimentally inflamed femoral arteries in vivo in a C57BL/6 and in an alipoprotein E-deficient (ApoE Ϫ/Ϫ ) mouse background and for exposure of adhesion molecules and recruitment of monocytes through the p38 mitogen-activated protein kinase (MAPK) pathway in vitro. These results support the role of this receptor as a key target for new antiinflammatory strategies in various diseases, including atherothrombosis.
Methods

Animals and Cells
Wild-type (WT), P2Y 1 Ϫ/Ϫ , ApoE Ϫ/Ϫ , and P2Y 1 /ApoE double knockout (P2Y 1 Ϫ/Ϫ /ApoE Ϫ/Ϫ ) male mice were of pure C57BL/6 background. Mouse microvascular endothelial cells (ECs) were isolated from murine lung by a method based on magnetic cell sorting, as described previously. 25 Murine monocytes were isolated from blood using a negative selection antibody cocktail and magnetic nanoparticles (StemCell Technologies, Grenoble, France). Bone marrow transplantation was performed on recipient 38 week-old male mice as described. 24 For continuous administration of MRS2500 into mice, a miniosmotic pump (Alzet, Palo Alto, CA) filled with 100 L MRS2500 (50 mg/mL), delivering 1 L/h, was implanted in the subcutaneous dorsal space of the mouse for 3 days.
Acute Vascular Inflammation In Vivo
For investigations in mesenteric venules, mice were treated with murine recombinant TNF␣ (250 ng in 300 L physiological saline) intraperi-toneally for 3 hours. For investigations in femoral artery, cytokines (50 ng TNF␣ and 12.5 ng IL-1␤ in 300 L physiological saline) were injected subcutaneously for 4 hours 26 into the medial region of the left hind foot under isoflurane anesthesia. Leukocyte-vessel wall interactions were visualized by in vivo labeling of leukocytes by intravenous injection of 3,3=-dihexyloxacarbocyanine iodide and were monitored in real time under a fluorescent microscope. The rolling leukocyte flux was determined as the number of leukocytes passing a reference line perpendicular to the blood flow during a 1 minute period.
In Vitro Monocyte EC Interaction and Transmigration
Confluent EC monolayers grown on IBIDI slides (Ibidi, Martinsried, Germany) were stimulated with TNF␣ (10 ng/mL) for 6 or 24 hours, and monocytes isolated from mice ubiquitously expressing green fluorescent protein were added to the EC monolayers for 2 hours at 37°C under mild agitation. Adherent cells were counted under a fluorescence microscope. For transendothelial migration assay, ECs were cultured on gelatin-coated Transwell membranes and treated for 24 hours with TNF␣ (10 ng/mL). Freshly isolated mouse monocytes (60ϫ10 3 ) were added to the upper chamber of Transwell inserts (Corning, Amsterdam, the Netherlands) containing 100 L of cell culture medium. Monocyte chemoattractant protein-1 (100 ng/mL)triggered transmigrated monocytes were harvested and counted.
Expression of Cell Adhesion Molecules
Expression of P-selectin, ICAM-1, and VCAM-1 on TNF␣ (10 ng/mL)-stimulated WT or P2Y 1 Ϫ/Ϫ ECs or on WT ECs in the presence or absence of MRS2500 was assessed by flow cytometry.
Measurement of DNA Binding Activity
Activating transcription factor 2 (ATF-2), nuclear factor B, or activator protein 1 DNA binding activities were measured by a sensitive ELISA-based assay using a Trans-AM Kit (Active Motif, Rixensart, Belgium).
Statistical Analyses
Statistical analyses were performed with GraphPad software (Prism 5.0). In vivo data were expressed as meanϮSEM, and were analyzed by 2-way ANOVA followed by the Bonferroni posthoc test ( Figure  1 ) or 1-way-ANOVA followed by the Bonferroni posthoc test ( Figure 2 ). In vitro data were expressed as meanϮSEM and analyzed by 2-way ANOVA followed by the Bonferroni posthoc test ( Figure  3 ) or by the Student t test ( Figure 4 ). In vitro data in Figure 5 were analyzed by 2-way ANOVA followed by the Bonferroni posthoc test, and in vivo data of Figure 6 were analyzed by Student t test. A value of PϽ0.05 was considered to be statistically significant.
Expanded Methods
Detailed Methods are described in the online-only Data Supplement.
Results
The P2Y 1 Receptor Is Involved in Leukocyte Recruitment During Acute Vascular Inflammation In Vivo
We first investigated whether the P2Y 1 receptor plays a part in leukocyte recruitment in the inflamed venules in vivo. Wild-type and P2Y 1 Ϫ/Ϫ mice were treated with murine recombinant TNF␣ (250 ng in 300 L saline) intraperitoneally, and the number of rolling leukocytes was evaluated 3 hours later in mesenteric venules. Tumor necrosis factor ␣-induced leukocyte rolling over the endothelium of WT mice (199Ϯ28 cells/min), whereas in P2Y 1 Ϫ/Ϫ mice the number of rolling leukocytes was reduced to 123Ϯ26 cells/min (nϭ8; Figure 1A ), suggesting a role for the P2Y 1 receptor in venule inflammation in vivo although statistical significance was not reached using 2-way ANOVA. Of note, considering only the TNF␣-stimulated mice, the difference in leukocyte recruitment was significant using a Mann-Whitney test.
We next investigated the role of the P2Y 1 receptor in the inflamed arteries. As arterial endothelium is less susceptible to cytokine stimulation, 26 WT and P2Y 1 Ϫ/Ϫ mice received a subcutaneous injection of a mixture of TNF␣ (50 ng) and IL-1␤ (12.5 ng), and the number of rolling leukocytes was evaluated 4 hours later in the femoral artery. Combined treatment with TNF␣ and IL-1␤ induced leukocyte recruitment in the femoral artery of WT mice (129Ϯ17 cells/min versus 0.2Ϯ0.2 cells/min; Figure 1B ). In P2Y 1 Ϫ/Ϫ mice, the number of rolling leukocytes was reduced to 73Ϯ16 cells/min (nϭ6, *PϽ0.05; Figure 1B ). These results indicate that the P2Y 1 receptor, without prejudging its cellular localization, is involved in leukocyte recruitment during acute arterial inflammation in vivo.
Key Role of Nonhematopoietic P2Y 1 Receptors in Leukocyte Recruitment in the Femoral Artery in ApoE ؊/؊ Mice
We wished to distinguish the relative contributions of the P2Y 1 receptors of blood cells (platelets, monocytes/macro-phages, and lymphocytes) and P2Y 1 receptors expressed in other tissues. Furthermore, we wanted to study this in a context of atherosclerosis. Therefore, 38-week-old male ApoE Ϫ/Ϫ and P2Y 1 Ϫ/Ϫ /ApoE Ϫ/Ϫ mice were sublethally irradiated and transplanted with bone marrow to give 4 groups of animals: ApoE Ϫ/Ϫ recipient mice transplanted with (1)
Thus, the nomenclature of the chimeras denotes firstly the P2Y 1 genotype of the hematopoietic cells, and secondly that of the rest of the body. Efficient bone marrow reconstitution was controlled in each recipient mouse by measuring the binding of Alexa-488 -labeled fibrinogen to platelets in response to ADP by flow cytometry (online-only Data Supplement Figure I ).
On injection of TNF␣ and IL-1␤, leukocyte rolling over the vascular wall was dramatically increased in the femoral arteries of WT-WT animals compared with mice receiving saline (222Ϯ50 cells/min, nϭ9, versus 0 cells/min, nϭ3; Figure 2A ). The absence of the P2Y 1 receptor in blood cells only (KO-WT mice) did not result in any reduction (236Ϯ64 cells/min, nϭ10, PϾ0.05), indicating that the P2Y 1 receptors of blood cells do not contribute to this process (Figure 2A) . In contrast, when the P2Y 1 receptor was absent in all cell types and tissues except blood cells (WT-KO mice) or in all cell types (KO-KO mice), the number of rolling leukocytes was strongly decreased (67Ϯ11 cells/min, nϭ10, and 107Ϯ43 cells/min, nϭ9, respectively; Figure 2A ). Consistent with these results, the difference in leukocyte recruitment between KO-WT and WT-KO mice was significant (236Ϯ64 cells/ min, nϭ10, and 67Ϯ11 cells/min, nϭ10, respectively; PϽ0.05). Leukocyte rolling was dependent on P-selectin, VCAM-1, and ICAM-1, because in ApoE Ϫ/Ϫ animals treated with blocking antibodies, leukocyte rolling was dramatically decreased ( Figure 2B ). Interestingly, in the P2Y 1 Ϫ/Ϫ / ApoE Ϫ/Ϫ mice, treatment with the same blocking antibodies only resulted in inhibition of residual P-selectin-dependent leukocyte recruitment, whereas the ICAM-1 and VCAM-1 antibodies had a very limited nonsignificant effect. Alto-gether, these findings point to a key role of the vascular P2Y 1 receptor in P-selectin-, VCAM-1-, and ICAM-1-dependent recruitment of leukocytes during acute arterial inflammation.
P2Y 1 Deficiency Impairs Monocyte Adhesion to and Transmigration Across TNF␣-Stimulated ECs In Vitro
In order to establish whether the endothelial P2Y 1 receptor was responsible for our in vivo observations, we investigated the TNF␣-mediated adhesion of isolated blood monocytes to primary cultured murine pulmonary ECs in vitro. Activation of ECs from WT mice with TNF␣ (10 ng/mL) for 24 hours resulted in a 1.6-fold increase in the adhesion of WT monocytes (PϽ0.05, nϭ7; Figure 3A) . In contrast, stimulation of P2Y 1
Ϫ/Ϫ ECs with TNF␣ resulted in only a very slight, if any, increase (1.2 fold) in monocyte adhesion (PϾ0.05, nϭ7; Figure 3A) . Thus, the specific contribution of the P2Y 1 receptor to TNF␣-induced increase in monocyte adhesion accounted for Ϸ70% of the total. These experiments were also run using WT ECs incubated with isolated P2Y 1 Ϫ/Ϫ blood monocytes, which displayed no decrease in adhesion compared with WT blood cells (data not shown).
Because these data indicated that the endothelial P2Y 1 receptor is strongly involved in TNF␣-induced adhesion of monocytes, we also investigated its role in their subsequent transmigration. In WT ECs, TNF␣ (10 ng/mL) significantly increased the transendothelial migration of monocytes triggered by MCP-1 (100 ng/mL) (Ϸ1.5-fold control, *PϽ0.05, nϭ6), whereas this enhancement was completely inhibited in P2Y 1 Ϫ/Ϫ ECs ( Figure 3B ). Here, the specific contribution of the P2Y 1 receptor accounted for Ϸ80% of the TNF␣-induced leukocyte transmigration. P2Y 1 deficiency did not however affect the basal MCP-1-triggered transendothelial migration of monocytes. Thus, the effects of TNF␣ on monocytes adhesion to and transmigration across ECs appear to be highly dependent on the presence of the endothelial P2Y 1 receptor.
The P2Y 1 Receptor Strongly Contributes to TNF␣-Induced Adhesion Molecule Exposure
Members of the selectin family, such as P-selectin 5 and the Ig family, notably ICAM-1 and VCAM-1, 6 promote adhesion of monocytes to the endothelium and their transmigration into the subendothelial space. To determine whether the P2Y 1 receptor plays a role in adhesion molecule exposure after TNF␣ stimulation, we used flow cytometry. Wild-type cultured pulmonary ECs expressed P-selectin, ICAM-1 and VCAM-1 under basal conditions, and this expression was significantly increased by TNF␣ (10 ng/mL) by 46Ϯ7% (1.46 fold), 177Ϯ30% (2.7 fold), 278Ϯ29% (3.8 fold), respectively. In contrast, exposure of P2Y 1 Ϫ/Ϫ ECs to TNF␣ resulted in reduced P-selectin (22Ϯ3% [1.2 fold], PϽ0.05, nϭ6), ICAM-1 (64Ϯ8% [1.6 fold], PϽ0.01, nϭ7) and VCAM-1 expression (113Ϯ23% [2.1 fold], PϽ0.001, nϭ7; Figure 4A ). The raw mean fluorescence intensity data are listed in the Table. Similarly, pretreatment of ECs for 48 hours with the selective P2Y 1 receptor antagonist MRS2500, before the addition of TNF␣, significantly inhibited the TNF␣ exposure of all 3 adhesion molecules (PϽ0.05, nϭ5 to 7; Figure 4B , online-only Data Supplement Table I) .
Western blot analysis showed increased expression of VCAM-1 and ICAM-1 after 24 hours' stimulation by TNF␣ (online-only Data Supplement Figure II) . In P2Y 1
Ϫ/Ϫ or MRS2500-treated ECs, basal levels of ICAM-1 were unchanged whereas its increase on stimulation by TNF␣ was inhibited. Relative to VCAM-1, both the basal and the stimulated levels of the protein were affected. Altogether these data suggest a role for the P2Y 1 receptor in the regulation of transcriptional mechanisms of these proteins. Overall, the results indicate an important role for the endothelial P2Y 1 receptor in the TNF␣-induced exposure and expression of adhesion molecules.
Role of P2Y 1 in TNF␣-Induced Activation of p38 MAPK in ECs
Tumor necrosis factor ␣ stimulation of adhesion molecules has been described as mediated by activation of the NFB pathway and a range of MAPKs including c-Jun N-terminal kinase and p38 MAPK. [27] [28] [29] No effect of P2Y 1 deficiency on the TNF␣-induced NFB and c-Jun N-terminal kinase/activator protein 1 signaling pathways could be detected under our experimental conditions (online-only Data Supplement Figures III and IV) . In contrast, we observed an impact of P2Y 1 deficiency or inhibition by MRS2500 on TNF␣induced activation of p38 MAPK. Whereas exposure of WT ECs to TNF␣ increased by Ϸ2 fold the phosphorylation of p38 MAPK, as assessed by Western blotting (*PϽ0.05, nϭ9), remarkably, ECs isolated from P2Y 1 Ϫ/Ϫ mice already presented a high level of p38 MAPK phosphorylation under resting conditions, Ϸ2.4 fold higher than in the WT (*PϽ0.05, nϭ9), with no additional response in the presence of TNF␣ (Figure 5A) , indicating a role of the P2Y 1 receptor in the regulation of the p38 MAPK basal activity. The ATF-2 transcription factor acts downstream of MAPK signaling to regulate the transcription of VCAM-1 and ICAM-1. 30, 31 Exposure of WT ECs to TNF␣ resulted in a significant increase in the DNA binding activity of ATF-2 (0.56Ϯ0.13 optical density units versus 0.31Ϯ0.08 optical density units in resting cells, PϽ0.05, nϭ6; Figure 5B ). Again, in P2Y 1 Ϫ/Ϫ cells a high level of ATF-2 activity (0.64Ϯ0.05 optical density units) was already observed in the absence of TNF␣ ( Figure 5B) , and TNF␣ had no additional effect (0.64Ϯ017 optical density units, PϾ0.05, nϭ6; Figure 5B ). These data suggest that the impact of P2Y 1 deficiency may result from dysregulation not only at the p38 MAPK level but also downstream of ATF-2.
In contrast, the selective P2Y 1 antagonist MRS2500 had no effect on the basal phosphorylation of p38 MAPK ( Figure  5C ) but prevented TNF␣-induced phosphorylation (PϽ0.05, nϭ6; Figure 5C ). Basal ATF-2 activity was not modified by MRS2500 whereas TNF␣-induced ATF-2 activity was partly inhibited ( Figure 5D ). This effect of MRS2500 was specific given that it had no effect on either p38 MAPK phosphorylation or ATF-2 activity in P2Y 1 Ϫ/Ϫ ECs (online-only Data Supplement Figure V) . These data indicate that the pharma-cological inhibition of P2Y 1 is associated with reduced p38 MAPK signaling and ATF-2 activity. Thus, both in P2Y 1deficient cells and after pharmacological inhibition, decreased expression of adhesion molecules seems to be related to reduced transcription, a finding that is also supported by transcriptome studies comparing WT and P2Y 1 Ϫ/Ϫ primary cultured mouse ECs, indicating that the genes for ICAM-1 and VCAM-1 are more weakly transcribed in P2Y 1 Ϫ/Ϫ ECs stimulated with TNF␣ (online-only Data Supplement Table  I ). This reduction is not due to decreased expression of the TNF␣ receptor itself as could be shown by Western blotting (data not shown).
Pharmacological Inhibition of Leukocyte Recruitment In Vivo
Bolus infusion of MRS2500 into mice had no effect on leukocyte recruitment in inflamed femoral arteries (data not shown). On the basis of our in vitro observation that a 48-hour preincubation period is required to inhibit TNF␣induced effects, we used continuous administration of MRS2500 via a miniosmotic pump implanted subcutaneously and delivering MRS2500 2.5 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 for 3 days. The control group had saline-loaded pumps. P2Y 1 receptor inhibition checked by measuring ADP-induced fibrinogen binding to platelets by flow cytometry showed that the P2Y 1 receptor was fully inhibited for the duration of administration (data not shown). After 3 days, MRS2500-treated animals displayed strongly reduced TNF␣/IL-1␤-induced leukocyte recruitment in the femoral artery (62Ϯ6 cells/min) compared with the controls (237Ϯ46 cells/min; Pϭ0.0038, nϭ6 mice per group; Figure 6 ). These results indicate that pharmacological inhibition of the P2Y 1 receptor potently inhibits acute vascular inflammation in mice.
Discussion
The most clear cut and striking observations of this study are (1) the major role of the vascular P2Y 1 receptor in the recruitment of leukocytes during acute inflammation of femoral arteries in healthy mice or in a context of murine atherosclerosis in vivo, (2) the very similar involvement of this receptor in TNF␣-induced adhesion molecule exposure and monocyte recruitment in cultured mouse endothelial cells (The latter in vitro results have been confirmed in primary cultured human coronary artery ECs, adding to the relevance of these data [online-only Data Supplement Figure VI] ), and (3) the pharmacological inhibition of leukocyte recruitment after administration of a selective antagonist of the P2Y 1 receptor. These findings may have important consequences for the management of vascular inflammation and of diseases like atherosclerosis.
A contribution of the P2Y 1 receptor to the development of atherosclerosis in double P2Y 1 /ApoE knockout mice was previously reported, and bone marrow transplantation experiments excluded the contribution of the platelet receptor. 24 The question remained, however, of whether the endothelial receptor or any other cell type expressing the P2Y 1 receptor was involved in atherosclerosis. The present findings strongly suggest that the endothelial receptor could be responsible for most of the observed effects. Deficiency of P2Y 1 or its pharmacological inhibition with MRS2500 markedly decreased both the TNF␣-induced expression of adhesion molecules and the recruitment of monocytes in cultured endothelial cells.
TNF␣ inflammatory stimulation of endothelial cells is mainly mediated through activation of the NF-B and p38 MAPK signaling pathways. 27, 32 Our data point to an important role of P2Y 1 in the p38 MAPK pathway. Notably, in P2Y 1
Ϫ/Ϫ cells the baseline phosphorylation state of p38 MAPK was strongly upregulated, with no further increase on TNF␣ stimulation. It is not yet known how the P2Y 1 receptor regulates the basal activity of p38 MAPK. A role for G protein-coupled receptor kinase 2 in the regulation of p38 MAPK activation has been reported. 33 It is feasible that the deficiency of the P2Y 1 receptor somehow increases the availability of G protein-coupled receptor kinase 2, which in turn results in increased phosphorylation of p38 MAPK. Now, because ATF-2 basal activity is increased in P2Y 1deficient ECs, the downstream stage where VCAM-1 and ICAM-1 transcription is reduced is not yet identified. Ongoing studies of the transcriptome of these cells under various experimental conditions should produce insights into the complex machinery of p38 MAPK-regulated transcription. Interestingly enough, the P2Y 1 antagonist MRS2500 had no effect on the basal activity of p38 MAPK, but inhibited its activation by TNF␣. Similarly, ATF-2 basal activity was not modified by MRS2500, which, however, inhibited its increase by TNF␣ ( Figure 5 ). The slight nonsignificant increase of ATF-2 activity, still observed in MRS2500-treated ECs on TNF␣ stimulation ( Figure 5D ), could rely on the difference in the p38 MAPK phosphorylation state between P2Y 1 deficiency and pharmacological inhibition of the receptor. Thus, the dysregulation caused by P2Y 1 deletion and resulting in high basal phosphorylation of p38 MAPK is accompanied by high ATF-2 activity, which could perhaps not be further stimulated by TNF␣. However, further work is required to fully explain this difference.
Previous reports have highlighted a link between the P2Y 1 receptor and p38 MAPK signaling. Thus, stimulation of P2Y 1 receptors by ADP has been associated with p38 MAPK activation in human platelets 34 and in ECs where this pathway was implicated in the ADP-induced migration of human umbilical vein ECs. 35 These data and our findings suggest that pharmacological inhibition of P2Y 1 might represent an interesting strategy to inhibit p38 MAPK-mediated vascular inflammation. Interestingly, treatment with the p38 MAPK inhibitor SB203580 has been shown to reduce atherosclerotic disease progression in ApoE Ϫ/Ϫ mice 36 and vascular inflammation in patients undergoing percutaneous coronary intervention. 37 Moreover, because insulin has been found to induce or potentiate TNF␣-induced VCAM-1 expression through a mechanism principally involving p38 MAPK, 38 -40 inhibiting P2Y 1 and thus, indirectly, TNF␣-induced activation of the p38 MAPK signaling pathway, might be particularly relevant in the case of hyperinsulinemia-associated diseases, such as type 2 diabetes mellitus. The search for antiinflammatory drugs that could efficiently prevent and treat atherosclerosis is very challenging, given that the existing drugs have numerous undesirable side effects. [41] [42] [43] Moreover, there is a need for compounds that can inhibit vascular inflammation in the absence of confounding effects. Indeed, although statins seem to have an antiinflammatory effect, they mostly act through their lipid-lowering effect. 44 The P2Y 1 receptor could be a relevant target for such compounds. Our results clearly demonstrate that administration of a P2Y 1 antagonist could inhibit leukocyte recruitment in vivo. The next steps will be to evaluate the impact of such compounds in vivo in models of atherosclerosis and type 2 diabetes mellitus. However, the current limitation for such studies is the lack of compounds with better pharmacokinetic profiles that could be administered continuously for a longer period of time.
In conclusion, our results clearly demonstrate a key role of the endothelial P2Y 1 receptor in acute arterial inflammation. Targeting the P2Y 1 receptor could represent a novel and promising approach for the treatment of acute and chronic vascular inflammation.
